Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • howcomethisdoesnotwork howcomethisdoesnotwork Jun 6, 2013 10:50 AM Flag

    After approval the revenue of the market is $ 35 Billion and expected to more than double in 5 years.

    After approval the revenue of the market is $ 35 Billion and expected to more than double in 5 years. If MNKD are successful in the super growth phase with a world class partnership, then Revenue from this 1 product not to mention other ones they may partake in after approval... could be easily $ 10-20 Billion by 2015. What would that translate to in share price, what kind of market cap ? about what and what share price. Am I incorrect that maybe it could be worth in short order something in the $ 75-$100 range ?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I can't quite figure out where the $35 Billion comes from. The existing prandial insulin market is listed as under $10 Billion worldwide, and most of that is in T1s.

      The T2 market for insulin is currently very small, mainly because RAA's create hypos and are too slow to effectively deal with the mealtime glucose spike. There will soon be 75 million T2s in the Western world, and this is the real market opportunity. Afrezza is the perfect treatment to stop progression of the disease in T2s by eliminating the post meal glucose spike. There is no real competitor in sight, and average insulin reimbursement exceeds $1k per year per patient in the Western world. JMHO.

      Sentiment: Buy

 
MNKD
1.35-0.09(-6.25%)Apr 29 4:00 PMEDT